Dataset Information

Short-Term Efficacy and Safety of Tolvaptan in Patients with Left Ventricular Assist Devices.

ABSTRACT: Tolvaptan is an effective therapy for heart failure patients with symptomatic congestion and hyponatremia. The efficacy of its use in patients with continuous-flow left ventricular assist devices (LVADs) is unknown. The aim of this study was to assess the clinical efficacy and safety of tolvaptan in LVAD patients. We retrospectively reviewed medical records of patients who underwent LVAD implantation between January 2014 and August 2018. Among 217 consecutive LVAD patients, tolvaptan was used in 20 patients. Mean age was 46 ± 14 years old and 14 patients were males. The duration of tolvaptan therapy was 4 (interquartile range 1-8) days. Urine volume significantly increased from 2,623 ± 1,109 ml/day before tolvaptan to 4,308 ± 1,432 ml/day during tolvaptan therapy (p < 0.001). Serum sodium increased from 127 ± 3 to 133 ± 3 mEq/L at the end of tolvaptan therapy (p < 0.001). No patients developed hypernatremia (serum sodium >150 mEq/L). The 90-day overall survival following tolvaptan therapy was 89% in both the tolvaptan group and a propensity score-matched non-tolvaptan group (p = 0.918). Survival free of heart failure readmissions was also comparable between the groups (p = 0.751). In conclusion, short-term use of tolvaptan following LVAD implantation is a safe and effective therapy to augment diuresis and improve hyponatremia.

SUBMITTER: Fujino T

PROVIDER: S-EPMC7340106 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Short-Term Efficacy and Safety of Tolvaptan in Patients with Left Ventricular Assist Devices.

Fujino Takeo T Imamura Teruhiko T Nguyen Ann A Chung Ben B Raikhelkar Jayant J Rodgers Daniel D Nitta Daisuke D Smith Bryan B Sarswat Nitasha N Kalantari Sara S Narang Nikhil N LaBuhn Colleen C Jeevanandam Valluvan V Kim Gene G Sayer Gabriel G Uriel Nir N

ASAIO journal (American Society for Artificial Internal Organs : 1992) 20200301 3

Tolvaptan is an effective therapy for heart failure patients with symptomatic congestion and hyponatremia. The efficacy of its use in patients with continuous-flow left ventricular assist devices (LVADs) is unknown. The aim of this study was to assess the clinical efficacy and safety of tolvaptan in LVAD patients. We retrospectively reviewed medical records of patients who underwent LVAD implantation between January 2014 and August 2018. Among 217 consecutive LVAD patients, tolvaptan was used in ...[more]

PMID: 31567410

Similar Datasets

Project description:BACKGROUND:The assessment of hemodynamics in patients supported with left ventricular assist devices (LVADs) is often challenging. Physical examination maneuvers correlate poorly with true hemodynamics. We assessed the value of novel transthoracic echocardiography (TTE)-derived variables to reliably predict hemodynamics in patients supported with LVAD. METHODS AND RESULTS:A total of 102 Doppler-TTE images of the LVAD outflow cannula were obtained during simultaneous invasive right heart catheterization (RHC) in 30 patients supported with continuous-flow LVADs (22 HMII, 8 HVAD) either during routine RHC or during invasive ramp testing. Properties of the Doppler signal though the outflow cannula were measured at each ramp stage (RS), including the systolic slope (SS), diastolic slope (DS), and velocity time integral (VTI). Hemodynamic variables were concurrently recorded, including Doppler opening pressure (MAP), heart rate (HR), right atrial pressure, pulmonary artery pressure, pulmonary capillary wedge pressure (PCWP), Fick cardiac output (CO) and systemic vascular resistance (SVR). Univariate and multivariate regression analyses were used to explore the dependence of PCWP, CO, and SVR on DS, SS, VTI, MAP, HR, and RS. Multivariate linear regression analysis revealed significant contributions of DS on PCWP (PCWPpred?=?0.164DS?+?4.959; R?=?0.68). Receiver operating characteristic (ROC) curve analysis revealed that PCWPpred could predict an elevated PCWP ?18 mm Hg with a sensitivity (Sn) of 94% and specificity (Sp) of 85% (area under the ROC curve 0.88). CO could be predicted by RS, VTI, and HR (COpred?=?0.017VTI?+?0.016HR?+?0.12RS?+?2.042; R?=?0.61). COpred could predict CO ?4.5 L/min with Sn 73% and Sp 79% (AUC 0.81). SVR could be predicted by MAP, VTI, and HR (SVRpred?=?15.44MAP?-?5.453VTI?-?6.349HR?+?856.15; R?=?0.84) with Sn 84% and Sp 79% (AUC 0.91) to predict SVR ?1200 dyn-s/cm5. CONCLUSIONS:Doppler-TTE variables derived from the LVAD outflow cannula can reliably predict PCWP, CO, and SVR in patients supported with LVADs and may mitigate the need for invasive testing.

Dataset Information

Short-Term Efficacy and Safety of Tolvaptan in Patients with Left Ventricular Assist Devices.

Publications

Short-Term Efficacy and Safety of Tolvaptan in Patients with Left Ventricular Assist Devices.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets